Niger
Tuberculosis profile
| High HIV burden |
Population  2013 18 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 3.1 (1.9–4.2) 17 (11–24)
Mortality (HIV+TB only) 0.37 (0.29–0.46) 2.1 (1.6–2.6)
Prevalence  (includes HIV+TB) 28 (15–46) 159 (83–257)
Incidence  (includes HIV+TB) 18 (16–20) 102 (91–115)
Incidence (HIV+TB only) 1.3 (1.1–1.4) 7.1 (6.3–7.9)
Case detection, all forms (%) 62 (55–69)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 1.9 (0.1–5.3) 20 (0.1–40)
MDR-TB cases among notified pulmonary
TB cases
180 (9–490) 130 (1–250)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 7 182   408
Pulmonary, clinically diagnosed 2 046    
Extrapulmonary 1 615    
       
Total new and relapse 11 251    
Previously treated, excluding relapses 232    
Total cases notified 11 483    
Among 7 182 new cases:
104 (1%) cases aged under 15 years; male:female ratio: 3.0
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 86 (13%) 86
Laboratory-confirmed RR-/MDR-TB cases     29
Patients started on MDR-TB treatment     40
TB/HIV 2013 Number (%)
TB patients with known HIV status 6 064 (53)
HIV-positive TB patients 419 (7)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 65 (16)
HIV-positive TB patients on antiretroviral therapy (ART) 161 (38)
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New cases registered in 2012 77
Previously treated cases registered in 2012 67
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011 86
XDR-TB cases started on second-line treatment in 2011 0
Laboratories 2013  
Smear (per 100 000 population) 1.1
Culture (per 5 million population) 0.3
Drug susceptibility testing (per 5 million population) 0.3
Sites performing Xpert MTB/RIF 1
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) 1.9
% Funded domestically 62%
% Funded internationally 38%
% Unfunded <1%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-04-28 Data: www.who.int/tb/data